Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • Interferon- and ribavirin-free DAA regimens recommended for the treatment of HCV infection in patients coinfected with HIV have shown to be highly tolerable with generally favorable safety profiles
  • The most important safety consideration for HCV therapy in patients with HCV/HIV coinfection are established and potential drug–drug interactions between HCV DAAs and antiretroviral agents

Action required

Keywords: Hepatic Complications, Special Populations, Treatment Complications, Viral Hepatitis Coinfection

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.